主权项 |
1. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with lung cancer, said method comprising
(a) obtaining a test sample from a patient undergoing said treatment regimen for lung cancer; (b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises MDC, NME-2, KGF, PIGF, Flt-3L, HGF, MCP1, SAT-1, MIP-1-b, GCLM, OPG, TNF RII, VEGF-D, ITAC, MMP-10, GPI, PPP2R4, AKR1B1, AmylA, MIP-1b, P-Cadherin, EPO, MMP-2, EGFR, MMP-3, ErbB2, cytokeratin-19, E-cadherin, IL-6, osteopontin, cKit, uPA, NSE, cMET, MDC, Flt-1, CEA, cytokeratin-8, KGF, S100A6, IL2-R, and combinations thereof; (c) comparing said level to a normal control level of said biomarker; and (d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen. |